Stereotaxis Inc. Common Stock (STXS)

FairStock Score: 42/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with owner earnings and financial strength. Stereotaxis sells robotic magnetic navigation systems for interventional labs, a specialized niche. But in fiscal 2025, the year ended 2025-12-31, revenue was $32.4M and net income was -$21.6M, or diluted EPS -$0.25. In fiscal 2024, revenue was $26.9M and net loss was $24.0M. So sales grew, but the company still lost money. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $7.7M and net loss $4.5M, versus revenue $8.8M and net loss $3.8M in fiscal Q2 2025. That recent trend is worse. FairStock's trailing free cash flow is -$15.5M, a -14.6% FCF yield against the $106.2M market cap at the 2026-10-13 close. At that same close of $1.06, the FairStock P/B is 8.15 and P/E is -4.42. The balance sheet shows D/E of 0.30, but Altman Z-score is -13.17, ROE is -184.27%, and ROCE is -25.38%. The Lynch category is none because it has lost money in each of the last four years, and the Piotroski F-Score is 4/9. FairStock Score is 42/100. A true moat should produce cash; here I see neither durable profits nor positive free cash flow. The technology may have promise, but without a visible path to profitability, I cannot call this a value investment.

In plain English: Stereotaxis makes robotic systems that help doctors guide catheters through blood vessels in the heart. The business is still losing money and using cash, and its latest reported quarter had lower sales than a year earlier. At $1.06, the stock looks inexpensive at first glance, but with no profits and ongoing losses, the numbers do not show a clear bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer